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ABSTRACT
Reves, Benjamin Taylor. Ph.D. The University of Memphis. August 2012.
Fabrication and Characterization of Multifunctional Chitosan Microspheres and Their
Incorporation Into Composite Scaffolds for Enhanced Bone Regeneration. Major
Professor: Warren O. Haggard, Ph.D.
Insufficient fracture healing affects hundreds of thousands of people every year in
the United States, resulting in devastating economic and social impacts. To treat these
severe fractures, our laboratory has developed chitosan-nano-hydroxyapatite
microspheres and scaffolds. The purpose of this research was to improve these scaffolds
by increasing their degradation rate to allow better bone ingrowth and to increase and
extend the elution of bone morphogenetic protein-2 (BMP-2) from the constructs. We
hypothesized that a composite approach combining chitosan and carboxymethylchitosan
microspheres would result in scaffolds with improved degradation and elution properties
while maintaining good cytocompatibility and sufficient mechanical properties.
The scaffold constructs are prepared by fusing chitosan microspheres together
using an acid wash to make the beads adherent. This approach promotes flexibility by
allowing multiple microsphere types to be incorporated into the scaffolds. Chitosan
microspheres with 80% degree of deacetylation were selected as the first component of
the composite scaffolds. These microspheres demonstrated good mechanical properties
(compressive modulus of 1.6 ± 0.3 MPa) and excellent cytocompatibility.
The second bead type was optimized for degradation and drug delivery. The
carboxymethylation of chitosan microspheres was performed using monochloroacetic
acid. The carboxymethylchitosan microspheres were crosslinked using two different
approaches: amine-amine crosslinking using genipin (Gen-X CMCS beads) and amide
bond formation using carbodiimide chemistry (X-CMCS). The Gen-X CMCS beads
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displayed poor degradation and elution properties; whereas, the X-CMCS beads
displayed extensive degradation (82.7 ± 1.2%) and extended elution of BMP-2 for at least
forty-five days. Composite X-CMCS/CS scaffolds were prepared and demonstrated
improved degradation and drug delivery compared to CS-only scaffolds while
maintaining sufficient mechanical characteristics and cytocompatibility.
This research demonstrated the advantages of using a composite approach and
supported our hypothesis. By optimizing each bead type for a specific purpose, the
overall properties of the scaffolds were improved. The combination of CS and X-CMCS
microspheres resulted in composite scaffolds that demonstrated excellent potential for
enhancing bone regeneration in severe fractures.
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PREFACE
The economic and social costs of insufficient fracture healing are enormous.
Roughly, $6.4 billion is spent each year in the United States to correct non-unions and
delayed healing in patients with severe fractures. The purpose of this research was to
fabricate and characterize an enhanced bone regenerative scaffold. The main body of this
dissertation contains the following manuscripts which have been published or will be
submitted for publication:

Chapter 2: Osteoinductivity Assessment of BMP-2 Loaded Composite ChitosanNano-Hydroxyapatite Scaffolds in a Rat Muscle Pouch. Published in Materials. 2011;
4: 1360-1374.

Chapter 3: Preparation and Functional Assessment of Composite Chitosan-NanoHydroxyapatite Scaffolds for Bone Regeneration. Published in Journal of Functional
Biomaterials. 2012; 3: 114-130.

Chapter 4: Fabrication and Characterization of Crosslinked
Carboxymethylchitosan Microspheres and Their Incorporation Into Composite
Scaffolds for Enhanced Bone Regeneration. Planned submission to Journal of
Biomedical Materials Research Part B: Applied Biomaterials (July 2012).
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Chapter 1 Introduction
1. Problem Statement
Of the approximate 8 million bone fractures that occur in the United States each
year, 5-10% of them will result in delayed healing or non-union [1, 2]. The economic and
social impacts of insufficient fracture healing are devastating, and a non-union can cost
upwards of $16,000/patient to correct [3]. Although autografts and allografts are
commonly used to treat severe fractures, they have a number of drawbacks [4-8]. For
these reasons, much research has focused on the development of bone tissue scaffolds.
These constructs provide a temporary matrix to which osteoblasts can attach and
proliferate, resulting in the formation of new bone [9, 10]. These scaffolds must meet a
number of requirements including the following: 1) appropriate surface chemistry to
favor cellular attachment, differentiation, and proliferation; 2) controlled degradability so
that tissue will gradually replace the scaffold; 3) adequate mechanical properties that
match the intended site of implantation; 4) interconnected porosity that promotes tissue
integration and vascularization; and 5) easy to manufacture, sterilize, and implant [1, 11].
Previously, our laboratories have developed chitosan-nano-hydroxyapatite scaffolds that
meet many of these requirements and have shown potential as a delivery device for the
local release of bone morphogenetic protein-2 (BMP-2) [12-14]. Although our
technology has shown promising results in vitro and in vivo, these scaffolds have
demonstrated slower degradation than desired and a less than optimal release profile of
BMP-2 [12, 14]. The goal of this project is to enhance the bone regenerative scaffolds by
improving their degradation and BMP-2 release profiles while maintaining their good
cytocompatibility and mechanical properties.
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2. Background
2.1. Fracture Healing
Roughly eight million bone fractures occur in the United States each year. Due to
the tremendous capacity of bone to heal itself, only 5-10% of these injuries will result in
delayed healing or non-union [1, 2]. These severe fractures are often caused by highimpact forces such as motor vehicle accidents, gunshot wounds, crush injuries, or
explosions. This type of injury leads to fractures in which the vasculature around the site
is severely damaged and the bone is fragmented into multiple pieces or even an entire
section of bone is missing [15-17].
Fracture healing occurs in three phases: early inflammatory stage, repair stage,
and late remodeling stage [15, 18, 19]. A hematoma is formed shortly after a fracture
occurs. Due to prostaglandin and growth factor release, a number of cell types migrate to
the fracture site including inflammatory cells, fibroblasts, and mesenchymal stem cells.
As vascularization improves, bone repair can proceed. A soft callus forms first which is
then replaced by a hard callus of woven bone. In the final stage of fracture healing, the
unorganized woven bone is remodeled into structured tissue with normal bone
architecture [15, 18, 19].
A number of growth factors play roles in the bone healing cascade. These proteins
include BMP-2, transforming growth factor-beta, fibroblast growth factor, plateletderived growth factor, and vascular endothelial growth factor [18, 20]. BMP-2 is very
important in bone repair, and it has even been shown that initiation of fracture healing
will not occur in the absence of endogenous BMP-2 [21]. BMP-2 is present in all three
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stages of fracture healing, and it promotes chemotaxis of stem cells to the fracture site,
angiogenesis, and the differentiation of stem cells into osteoblasts [20, 22-26].
2.2. Current Treatment Strategies
Bone grafts are often used to aid healing of severe fractures, and autograft
procedures are the current gold standard treatment. An autograft is obtained from a
different location on the patient’s body, such as the iliac crest of the hip. Drawbacks for
autograft procedures include surgical site infection, difficulty shaping the graft to fit the
defect, requirements of additional surgical procedures, extended recovery times, and
donor site morbidity [4, 5, 7, 8]. An allograft is a graft retrieved from a different person,
typically a cadaver. Allografts have demonstrated variable efficacy and are associated
with immunologic concerns [1, 5, 6]. Demineralized bone matrix (DBM) is prepared by
removing the inorganic portion of bone, leaving behind the non-mineralized matrix and
associated proteins. DBM products have demonstrated considerable variability in
efficacy and are unreliable [27, 28].
For these reasons, much research has focused on the development of bone graft
substitutes. These constructs must meet a number of requirements as previously
described. Many technologies meet some of the needed characteristics, but very few meet
all of them. For instance, scaffolds composed of strong materials like polycaprolactone
and polyurethane have good mechanical strength but degrade very slowly [29, 30].
Collagen sponges and alginate, agarose, and hyaluronic acid hydrogels are degradable,
but have compressive moduli orders of magnitude less than that of trabecular bone [3134]. The brittle nature and poor fatigue resistance of many bioceramics, such as calcium
phosphates and bioactive glasses, limits their usefulness in treating large bone defects
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[35, 36]. Popular degradable polyesters, including polyglycolide and polylactide, have
undesirable acidic degradation byproducts that can negatively impact bone repair [10,
37].
Many bone graft substitutes are also used as local drug delivery devices for
growth factors and/or antibiotics [9, 20, 38, 39]. Release of BMP-2 from bone scaffolds
has received much attention, due to the growth factor’s importance in the bone healing
cascade. Some success has been achieved clinically, but the full potential of BMP-2 in
augmenting fracture repair has not been realized. The main hindrance thus far has been
the inability to provide sustained delivery of physiologically relevant levels of BMP-2 [7,
9, 37, 40-42]. Many of the currently available BMP-2 delivery materials demonstrate a
burst release, and as much as 80% of growth factor activity is lost after forty-eight hours
post-implantation [43]. Excessive amounts of costly BMP-2 are loaded initially due to
BMP-2’s very short half-life of 7-16 minutes in vivo [9, 41, 44-46]. These
supraphysiological levels of growth factor released within the first few hours after
surgery do not aid healing and can cause adverse side effects, such as ectopic bone
formation, soft tissue swelling, and bone cysts [10, 45-49]. Indeed, a number of studies
have shown that the extended delivery of BMP-2 throughout the bone healing cascade is
more effective that a large initial burst release of BMP-2 [40, 45, 46, 50-52]. By
delivering BMP-2 more efficiently, less total BMP-2 would be required, and the number
of complications and health care costs associated with augmentation of fracture repair
may potentially be decreased [7, 46].
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2.3. Previous Work
Our laboratory has developed chitosan-nano-hydroxyapatite microspheres and
scaffolds to enhance healing in severe fractures [12-14]. The chitosan-nanohydroxyapatite microspheres are prepared using a co-precipitation method. Porous
scaffolds are then fabricated by washing the beads in 1% acetic acid for approximately
ten seconds. The acid slightly dissolves the outermost portions of the microspheres and
makes them adherent. Chitosan is natural carbohydrate co-polymer containing
glucosamine and N-acetyl-D-glucosamine units. Chitosan has biocompatible,
osteoconductive, mucoadhesive, and enhanced would healing capabilities and has been
used in numerous biomedical applications including orthopaedic tissue engineering [11,
53-58]. Hydroxyapatite is a crystalline calcium phosphate and is the main inorganic
component of bone [59]. Hydroxyapatite has been incorporated into implants and
scaffolds to enhance the response of osteoblasts [60-66].
Our chitosan-nano-hydroxyapatite scaffolds have shown good potential for use in
bone regenerative applications. Chesnutt et al. demonstrated the cytocompatibility of our
scaffolds with human fetal osteoblast cells, and the scaffolds were found to be
osteoconductive in vivo in a rat calvarial defect [12, 13]. Reves et al. demonstrated the
feasibility of using the composite as a drug delivery device for elution of BMP-2 [14].
Although the technology showed great promise in augmenting fracture healing, areas for
improvement were noted. The microspheres and scaffolds demonstrated slow degradation
in vitro and in vivo. Chesnutt et al. measured less than three percent degradation of the
chitosan-nano-hydroxyapatite scaffolds in a 500μg/mL lysozyme solution [12-14]. The
goal of bone regeneration is for new bone to completely replace the temporary matrix
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over time. If the scaffolds do not degrade in a timely manner, limited tissue ingrowth will
occur and fracture healing will be impaired [9, 67, 68]. Also, a significant burst effect
release of BMP-2 from the chitosan scaffolds was observed [14]. As previously
discussed, an extended elution of BMP-2 is desired over a large burst release.
2.4. Carboxymethylchitosan
Chitosan is a versatile material containing a number of hydroxyl and amine
groups that allow for numerous modification strategies [11, 55, 56]. One such strategy is
the carboxymethylation of chitosan using monochloroacetic acid [69-72]. Since
carboxymethylchitosan (CMCS) is water-soluble, it is often crosslinked to form
hydrogels. CMCS contains both amine and carboxyl groups, and 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) can be used to crosslink CMCS by forming
amide bonds [70, 72-75]. Genipin, a natural amine-amine crosslinker derived from the
Gardenia plant, has been used to crosslink chitosan and CMCS. Genipin is of interest for
use in biomedical applications, since it has demonstrated excellent cytocompatibility
compared to other commonly used crosslinkers such as glutaraldehyde [76-80]. Most
research using EDC or genipin to crosslink CMCS has been performed in solution or on
highly porous constructs. The feasibility of using these chemicals to crosslink dense
CMCS microspheres has not been investigated.
Carboxymethylchitosan (CMCS) films and gels have demonstrated good
biocompatibility [70-72, 81-83]. In addition, CMCS constructs have increased
degradation compared to their chitosan counterparts. Wang et al. measured a 70%
reduction in the mass of CMCS tubes compared to only 4.3% for chitosan tubes [70, 72].
Thus, the carboxymethylation of chitosan microspheres is expected to increase their
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degradability. The addition of a carboxyl group to the chitosan beads may also improve
their BMP-2 elution profile. The isoelectric point of BMP-2 is approximately 9.0, which
means that BMP-2 will have a net-positive charge at neutral pH [4, 84, 85]. The presence
of a negatively-charged carboxyl group may promote interaction between BMP-2 and
CMCS leading to a more extended elution. The inclusion of CMCS microspheres into
chitosan scaffolds is expected to improve the degradation and BMP-2 delivery properties
of the constructs.
3. Hypothesis
Chitosan scaffolds with beads prepared using a single microsphere fabrication
method are not expected to meet all the characteristics required of a bone graft substitute.
We believe a better strategy is to incorporate multiple bead types into the scaffolds, and
each bead type in the construct should be optimized for a particular purpose. Specifically,
we hypothesized that composite scaffolds composed of CMCS and chitosan microspheres
would result in constructs with increased degradation and extended BMP-2 release
compared to chitosan-only scaffolds, while maintaining good biocompatibility and
sufficient mechanical properties.
The goal of this research was to develop an improved bone regenerative scaffold,
and this dissertation is organized in the following manner. The second chapter describes
an in vivo osteoinductivity study in which the ability of BMP-2 loaded chitosan-nanohydroxyapatite scaffolds to form bone in a rat muscle pouch was determined. The results
of this investigation demonstrated the need for enhancement of our scaffold technology.
At this point, a multi-bead scaffold was envisioned. The third chapter describes the
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optimization of the chitosan bead component of the scaffolds. The fabrication and
incorporation of CMCS beads into composite scaffolds is described in the fourth chapter.
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Chapter 2 Osteoinductivity Assessment of BMP-2 Loaded Composite ChitosanNano-Hydroxyapatite Scaffolds in a Rat Muscle Pouch
1. Introduction
Of the approximate eight million bone fractures that occur in the United States
each year, 5-10% of these fractures will result in delayed healing or non-union [1]. The
current gold standard for augmenting healing in these troublesome fractures is the use of
autografts. However, autografts suffer from a number of drawbacks including surgical
site infection, difficulty shaping the graft to fit the defect, donor site morbidity, and
limited graft material [2-4]. Allografts are not as effective as autografts and transmission
of disease from the donor remains a concern [3-5]. Demineralized bone matrix displays
extremely varying rates of effectiveness [6,7]. For these reasons, much current research
has focused on the development of bone regeneration scaffolds that can be used as bone
graft substitutes. These scaffolds are designed to provide a matrix to which osteoblasts
can attach and proliferate. Ideally, the scaffolds will provide mechanical strength initially
and then degrade as new bone is deposited [8,9]. Our laboratories have developed
composite chitosan-nano-hydroxyapatite scaffolds to enhance fracture healing [10-12].
After cellulose, the most abundant biopolymer is chitin. Chitin is found in the
exoskeletons of crustaceans and insects [13,14]. The deacetylated derivative of chitin is
known as chitosan, and chitosan is a carbohydrate copolymer composed of glucosamine
and N-acetyl-D-glucosamine units joined by β-1,4 glycosidic bonds. If the copolymer
contains more than 50% glucosamine units, it is referred to as chitosan; whereas, it is still
called chitin if it retains more than 50% N-acetyl-D-glucosamine monomers [15,16].
Chitosan has a number of properties including biocompatibility, biodegradability,
mucoadhesiveness, and wound healing capabilities that make it useful as a biomaterial.
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Chitosan is very versatile and can be prepared as films, gels, sponges, beads, fibers and
other forms and has been used in various applications including wound healing, drug
delivery, and bone tissue engineering [14-20].
Ideally, scaffolds used for bone regeneration need mechanical strength [8]. The
pores of the scaffold must remain open to allow tissue ingrowth into the interior of the
scaffolds and to maintain good nutrient/waste exchange [21,22]. Our composite scaffolds
incorporate the strength and hardness of hydroxyapatite with the toughness and flexibility
of chitosan. Hydroxyapatite is the main inorganic component of bone and has been used in
coatings to improve osteoblast response to implants [9,14,23-26]. In addition, our labs have
demonstrated the enhanced bone regenerative capacity of composite scaffolds over
chitosan-only scaffolds [10,11].
To further increase the bone regenerative properties of graft substitutes, the
scaffolds can also serve as a carrier for the local delivery of growth factors [21,27,28].
Bone morphogenetic protein-2, BMP-2, has been widely investigated for augmenting
fracture healing due to its pleiotropic nature. BMP-2 recruits stem cells to the fracture
site, promotes angiogenesis, and causes differentiation of the stem cells into osteoblasts
[27,29-33]. We have previously shown that increased BMP-2 loading can be achieved
using composite scaffolds instead of chitosan-only scaffolds. We also demonstrated that
even further BMP-2 loading can be achieved using lyophilization (freeze-drying) to
increase the surface area of the scaffolds [12].
The objective of this investigation was to evaluate the osteoinductivity of BMP-2
loaded composite chitosan-nano-hydroxyapatite scaffolds in a rat muscle pouch model.
The murine muscle pouch model is a well-established model for determining the
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osteoinductivity of materials [34-36]. We hypothesized that the lyophilized composite
scaffolds would induce the most bone formation due to enhanced BMP-2 loading.
2. Results and Discussion
Porous composite scaffolds were successfully prepared by fusing chitosan-nanohydroxyapatite beads together using an acid wash (Figure 1). The initial porosity of the
non-lyophilized and lyophilized scaffolds were 35.8 ± 2.1% and 53.6 ± 3.6%,
respectively [12]. Thus, the lyophilized scaffolds are slightly more porous than the nonlyophilized scaffolds. It has been suggested that a minimum porosity of thirty percent is
required for bone regeneration [37]. In addition, the 100–800 micron pore diameters of
the composite scaffolds are suitable for bone regeneration [10], since pores of at least one
hundred microns are required for osteogenesis [9].
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Figure 1. Scanning electron micrograph (SEM) images of composite scaffolds and
microspheres. A) Non-lyophilized composite scaffold, 30×. B) Lyophilized composite
scaffold, 30x. C) Surface of non-lyophilized composite microsphere, 1600×. D) Surface
of lyophilized composite microsphere, 1600x. Note the slightly increased porosity of the
lyophilized scaffolds. The surface of the lyophilized microsphere is considerably rougher
than the surface of the non-lyophilized microsphere.

Following implantation into rat muscle pouches for one month, the osteoinductive
potential of the composite scaffolds was determined. Using BIOQUANT OSTEO II
imaging software, the amount of residual implant material, osteoid, and new bone as a
percent of total implant area were quantified (Table 1). The remaining space in the
implant area was occupied by fibrous or muscle tissue.
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Table 1. Composite scaffold performance. N/A: Not applicable; a: Bone and marrow.
Scaffold Type
Scaffold (%)
Osteoid (%)
Bone (%)
Lyophilized (no rhBMP-2)

65.2 ± 3.7

8.8 ± 2.6

1.8 ± 0.8

Lyophilized with rhBMP-2

59.2 ± 6.1

10.4 ± 1.2

1.2 ± 0.3

Non-lyophilized with
rhBMP-2
Collagen Sponge with
rhBMP-2

71.8 ± 3.0

7.7 ± 2.4

1.0 ± 0.7

N/A

N/A

94.0 ± 4.4a

As seen in Table 1 and displayed in Figure 2, the majority of the implant space
was still occupied by scaffold material after one month. Recall that the initial porosities
of non-lyophilized and lyophilized scaffolds were 35.8 ± 2.1% and 53.6 ± 3.6%,
respectively [12]. Thus, no degradation was observed, and the scaffolds actually appeared
to increase in mass slightly during this experiment. This slight increase may be due to
histological artifacts. Also, the amount of remaining chitosan was determined by
evaluating thin slices through the scaffold; whereas, the initial porosity was determined
using slices through the entire scaffold obtained by Micro-CT. Using the same 92.3%
degree of deacetylation (DDA) chitosan, Chesnutt et al. observed no measurable
degradation during a two-week in vitro degradation study and very minimal degradation
during a 12-week rat calvarial defect model [10,11].
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Figure 2. Light microscope image of representative histology section, H&E stain. The
bright red objects are residual scaffold material. Note that most of the implant space is
still occupied by scaffold material. Some histological artifacts are present in this
particular section. Scaffold type was non-lyophilized with rhBMP-2.

As previously discussed, controlled degradation is an important characteristic of
bone regenerative scaffolds. If the scaffolds do not degrade in a timely manner, extensive
new bone formation will be prevented due to lack of space [21,38,39]. The 92.3% DDA
chitosan used in this study was chosen due to its good mechanical properties; however,
chitosan with a lower DDA has been shown to degrade considerably faster [18,40]. As
DDA decreases, so does the crystallinity of the chitosan. This lower crystallinity allows
lysozyme, the main enzyme responsible for chitosan degradation in vivo, easier access to
the glycosidic bonds between the monomers [18,41]. Other potential methods for
increasing scaffold degradation include using a lower molecular weight chitosan,
decreasing the weight percent of chitosan, and using other solvent acids.
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The composite chitosan-nano-hydroxyapatite scaffolds appeared to be very
biocompatible. No adverse tissue reactions were observed. A small amount of new bone
was seen in the implant area for all three groups (Figures 3, 4, and 5).

Figure 3. Light microscope image of lyophilized scaffold without rhBMP-2, H&E stain.
The bright red objects are residual scaffold material. New bone tissue near and adjacent
to the scaffold is present. An extensive amount of osteoid material which is in the process
of becoming mineralized is also evident. Some capillaries with red blood cells in their
interior can be seen. C: residual chitosan, B: bone, O: osteoid, *: capillaries.
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Figure 4. Light microscope image of lyophilized scaffold with rhBMP-2, H&E stain. The
bright red objects are residual scaffold material. Some bone has formed in the pores of
the scaffold. The remaining tissue appears to be osteoid material in the process of
becoming mineralized. C: residual chitosan, B: bone, O: osteoid.

Figure 5. Light microscope image of non-lyophilized scaffold with rhBMP-2, H&E stain.
The bright red objects are residual scaffold material. Bone and osteoid are occupying the
pores of the scaffold. C: residual chitosan, B: bone, O: osteoid.
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The amount of new bone was not statistically different between the groups (p =
0.16). It was somewhat surprising that new bone was found in the lyophilized scaffolds
without BMP-2. Both chitosan [14,15,21] and hydroxyapatite [4,35,42] are considered to
be osteoconductive, meaning that they are able to support the attachment and proliferation
of bone cells but do not have the ability to cause stem cells to differentiate into osteoblasts.
Furthermore, various composite chitosan-hydroxyapatite preparations have been shown to
be osteoconductive [43-46]. However, some in vitro and in vivo data claiming
hydroxyapatite to be osteoinductive does exist. Lin et al. demonstrated the ability of
porous hydroxyapatite to induce expression of genes for alkaline phosphatase,
osteocalcin, and Type I collagen in uncommitted pluripotent C3H10T1/2 mouse stem
cells [47]. Porous nanohydroxyapatite/polyamide 66 scaffolds were found to be
osteoinductive in New Zealand white rabbit muscle pouches by Xu et al. [48].
Hydroxyapatite has also been shown to be osteoinductive in large animals. Ripamonti et
al. have demonstrated the ability of hydroxyapatite disks derived from coral and
hydroxyapatite disks prepared using a solid-state reaction to be osteoinductive when
implanted intramuscularly in baboons [49,50]. A number properties including
topography, surface energy, surface area, and crystallinity of hydroxyapatite and other
calcium phosphate materials are crucial in determining their osteoconductive and
osteoinductive potentials [25,51-54]. In this study, the scaffolds appear to have the right
combination of these surface chemistry and microarchitecture properties to impart some
degree of osteoinductivity. It should also be noted that in the current experimental design,
each rat received two scaffolds (one in each bilateral pouch); thus, it is possible that
BMP-2 was able to diffuse from one implant site to another. However, proteolytic
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enzymes are expected to quickly degrade any diffusing BMP-2, and the half-life of BMP2 is 7-16 minutes [55]. Thus, we believe the presence of new bone in the scaffold group
without BMP-2 is an indication that our composite scaffolds are very suitable for bone
regeneration. It is also very promising that new bone was observed in direct contact with
the composite scaffolds.
While the amount of new bone observed for the composite scaffolds was low,
more mineralized tissue might have been observed if a later timepoint had been used.
However, considerable amounts of osteoid were observed for the three experimental
groups. Thus, significant regions of unmineralized matrix which were expected to be later
mineralized and converted to bone were observed. Since the composite scaffolds did not
degrade and occupied a large portion of the implant area, the amount of new bone and
osteoid were normalized to the amount of space available for tissue formation by
calculating the bone tissue index (BTI) using the following equation:

BTI 

( Bone  Osteoid )
 100%
(100  Scaffold )

(1)

Thus, the BTI is an indicator of how much of the open pore space in the implant
area was filled in with new bone or was in the process of being converted to bone after
one month. Table 2 displays the BTI for the experimental groups.

Table 2. Bone Tissue Index (BTI) values for composite scaffolds.
Scaffold Type
Lyophilized (no rhBMP-2)
Lyophilized with rhBMP-2
Air-dried with rhBMP-2

Bone Tissue Index (%)
30.6 ± 8.5
28.8 ± 5.4
30.5 ± 5.7
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The values of the BTIs for all three groups were approximately thirty percent and
were not statistically different (p = 0.90). This degree of bone and osteoid formation is
comparable to that observed in studies with other non-degrading porous implant
materials. Baril et al. observed 20–25% bone ingrowth after six weeks into the pores of
titanium implants with approximately 50% porosity [56]. Only 11.4 ± 2.4 and 10.5 ±
1.8% of bone ingrowth as a percent of void space after twelve weeks was observed by
Willie et al. in titanium foam implants with porosities of 74.4 and 79.0%, respectively
[57]. Following implantation of hydroxyapatite implants with 50% porosity into the
femoral condyles of rabbits, Wang et al. observed 2.54 ± 0.59% bone ingrowth (as a
percent of total defect area) after three weeks [58]. This value is similar to the bone
ingrowth observed after four weeks in our chitosan-nano-hydroxyapatite scaffolds.
However, Wang et al. found no bone in the interior region of their implants; whereas, new
bone was found in the interior region of our scaffolds directly adjacent to composite beads.
After three weeks of implantation in rat tibial defects, Zreiqat et al. observed approximately
25% bone ingrowth into pores of ceramic Hardystonite (77.5% porosity) and SrHardystonite (78% porosity) [59]. Thus, we believe that our composite chitosan-nanohydroxyapatite scaffolds have similar or potentially improved osteogenic capacity compared
to the discussed biomaterials.
The experimental group containing lyophilized scaffolds with BMP-2 was
expected to perform the best in this study due to increased BMP-2 loading. However, our
hypothesis was not confirmed. The lack of degradation by the scaffolds may have
reduced the effectiveness of BMP-2 delivery, since there was little space for new bone to
be deposited. Also, the success of BMP-2 delivery depends upon the release profile of the
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specific carrier [60-62]. Although there is some debate over what type of delivery profile
is optimal for promoting osteogenesis, evidence suggests that a small to moderate burst
release followed by sustained release of BMP-2 may be most effective [63-65]. In vitro
characterization of BMP-2 elution from the composite scaffolds revealed a large burst
release in which the majority of the growth factor was released within the first few days
[12]. Perhaps more new bone would have been seen in the BMP-2 groups if a more
optimal release profile occurred. We believe that the 36μg of BMP-2 per implant used in
this study was an appropriate amount. Levels as low as
1.0 μg [60] to as high as 150 μg [66] of BMP-2 have been used successfully in similar
murine ectopic bone models. Engstrand et al. observed greatly increased bone volume
when 50 μg of BMP-2 was delivered compared to 10 μg [61]. An amount of 20μg of
BMP-2 maintained ectopic bone formation better than 10, 5, or 2.5 μg in a study by Lee
et al. [67].
Somewhat surprisingly, the increased total porosity of the lyophilized scaffolds
did not result in increased new bone formation compared to non-lyophilized scaffolds.
The non-lyophilized scaffolds did have the lowest value for amount of new bone (Table
1), but this value was not statistically significant. The differences in porosity between the
non-lyophilized and lyophilized scaffolds
(35.8 ± 2.1 and 53.6 ± 3.6, respectively) may not have been enough to considerably alter
bone tissue formation. Although only a small amount of new bone was observed in this
study, our composite scaffolds were able to promote and sustain ectopic bone growth.
Furthermore, bone was found in the interior of the scaffolds and in direct contact with the
scaffolds. We believe that our technology can be modified to produce scaffolds with a
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faster degradation rate and that these scaffolds will be able to support extensive bone
formation.
The BMP-2 loaded absorbable collagen sponge used as a positive control in this
study completely degraded after one month and the implant area was filled in with bone
and adipose tissue. Bone or adipose tissue (indicative of marrow formation) filled in 94.0
± 4.4% of the implant area. No adverse tissue response to the material was observed
(Figure 6).

Figure 6. Light microscope image of absorbable collagen sponge, H&E stain. The
collagen sponge has completely resorbed and is being replaced with bone. Fat globules
indicative of marrow formation can also be seen. B: bone, F: fat globules.

The BMP-2 loaded absorbable sponge promoted extensive osteogenesis as
expected. This sponge is used clinically to promote interbody spinal fusion and in the
treatment of open tibial fractures. Although the sponge degrades quickly to allow
extensive new bone formation, the collagen sponge cannot provide mechanical support to
the fracture site and must be used in conjunction with hardware to prevent collapse of the
defect [68].
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3. Experimental Section
3.1. Composite Microsphere and Scaffold Fabrication
Composite microspheres and scaffolds were prepared as previously described
[12]. Firstly, microspheres were fabricated using a co-precipitation method. A solution
containing 3.57 weight percent (wt. %) chitosan (92.3% DDA; Mv = 4.66 × 105 g/mole;
Vanson, Redmond, WA), 0.1M CaCl2, and 0.06 M NaH2PO4 (Ca:P ratio = 1.67) was
prepared in 2 wt. % acetic acid. A precipitation solution (pH = 13) containing 20 wt. %
NaOH, 30 wt. % methanol, and 50 wt. % water was prepared. Using a syringe pump, the
chitosan solution was added dropwise through 21G needles into the precipitation
solution, and spherical microspheres immediately formed. The composite microspheres
were allowed to wash in the precipitation solution for 24 h to allow crystalline
hydroxyapatite to form. The microspheres were then washed in deionized (DI) water until
a neutral pH (<7.5) was achieved.
Porous composite scaffolds were formed by adhering the microspheres together.
The microspheres were briefly rinsed in 1 wt. % acetic acid and packed into 13mmdiameter plastic tubes to dry. Once the scaffolds had completely dried, they were
rehydrated in DI water and cut into cylinders with an approximate height of 4mm and
diameter of 5.75 mm. Some of the scaffolds were allowed to dry again; whereas, some of
the rehydrated scaffolds were placed in a freezer at −20 °C and subsequently lyophilized
in a 2.5 L Labconco freeze-dryer. All scaffolds were sterilized using 25 kGy
gamma irradiation.
3.2. Scaffold Preparation for Surgery
The following groups (n = 6) were prepared for implantation into rat muscle
pouches: A) lyophilized scaffolds without rhBMP-2, B) lyophilized scaffolds with
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rhBMP-2 (Genetics Institute, Cambridge, MA), C) non-lyophilized scaffolds with
rhBMP-2, and D) absorbable collagen sponge (Medtronic, Inc., Memphis, TN) with
rhBMP-2. The collagen sponge was aseptically cut into pieces 1 cm. × 1 cm. A 9.0μg/mL
solution of rhBMP-2 was prepared in sterile water. An amount of 4 mL of rhBMP-2
solution was added to Groups B, C, and D for 48 h in sterile glass vials. After 48 h, the
loading solution was aspirated and the scaffolds were stored in the glass vials at 4 °C until
the surgeries.
3.3. Animal Surgeries
All procedures described were approved by the Institutional Animal Care and Use
Committee at the University of Memphis (Protocol #0639) and conform to the laws and
regulations of the United States. Upon arrival, twelve three-to-four month-old male
Sprague Dawley rats were allowed to acclimate for one week. For surgery, rats were
anesthetized with a subcutaneous injection of telazol. The back of each rat was shaved
and scrubbed with betadine. A single 1.5 cm incision was made through the skin on each
side of the midline. In each incision, a 1 cm pouch was created in the latissimus dorsi
muscle using blunt dissection. A single randomized test specimen was implanted in each
muscle pouch. Following implantation, the muscle and skin incisions were closed with 40 Vicryl sutures.
The rats were sacrificed after one month. The implants and surrounding tissue
were excised and stored in 10% formalin. Following decalcified histological processing,
three sections of each sample were stained with hematoxylin and eosin. Using the
BIOQUANT OSTEO II v.8.10.20 imaging system, the total implant area in each section
was identified. Sections were analyzed for amount of residual implant material, new
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bone, and osteoid as a percent of total implant area. One-way analysis of variance
(ANOVA) was performed to determine statistical significance between groups with
p < 0.05 considered significant.
4. Conclusions
The ability of composite chitosan-nano-hydroxyapatite scaffolds to promote
ectopic bone formation in a rat muscle pouch was demonstrated. Interestingly, both
BMP-2 loaded scaffolds and scaffolds without BMP-2 were also able to promote
osteogenesis. Increased bone formation due to local BMP-2 delivery was not observed,
possibly due to the lack of degradation exhibited by the scaffolds. Also, the large burst
effect release of BMP-2 from the composite scaffolds may not have been the optimal
elution profile to promote ectopic bone growth. Although new bone formation in the total
implant area was minimal (less than 2%), roughly thirty percent of the void space of the
composite scaffolds contained bone or osteoid after one month. An absorbable collagen
sponge loaded with BMP-2 used as a positive control completely degraded after one
month, and 94.0 ± 4.4% of the implant area contained new bone or marrow.
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Chapter 3 Preparation and Functional Assessment of Composite Chitosan-NanoHydroxyapatite Scaffolds for Bone Regeneration
1. Introduction
Approximately, five to ten percent of bone fractures will result in delayed healing
or non-union [1]. In Europe, insufficient bone healing results in socioeconomic losses of
around 14.7 billion euros each year [2]. Although autografts and allografts are commonly
used to treat these troublesome fractures, a number of drawbacks with these procedures
have generated interest in the development of bone graft substitutes [3-6]. These bone
graft substitutes are designed to provide a favorable matrix to which osteoblasts can
attach, proliferate, and subsequently produce new bone. These materials are also expected
to provide some mechanical support and stability to the fracture site until osteogenesis
occurs. In addition, these bone scaffolds should degrade in a timely manner so that new
bone can completely fill the defect site [7-10]. Many of these scaffolds also serve as drug
delivery vehicles for the local release of growth factors to further augment fracture
healing [2, 11, 12].
Our laboratory group has previously developed chitosan-nano-hydroxyapatite
scaffolds for use in bone regeneration [13-15]. The scaffolds are prepared by fusing
composite microspheres together to form porous scaffolds. Chitosan is a carbohydrate copolymer containing glucosamine and N-acetyl-D-glucosamine monomers[16, 17].
Chitosan displays a number of properties including biocompatibility, degradability,
mucoadhesiveness, and an ability to promote wound healing that have led to the
development of chitosan sponges, films, gels, beads, etc. for use in various biomedical
applications [16-20]. Hydroxyapatite is the main inorganic component of bone and has
been used to improve osseointegration of implants and in bone graft substitutes [20-23].
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We have previously demonstrated the potential of these composite chitosan-nanohydroxyapatite scaffolds to serve as bone graft substitutes both in vitro and in vivo [1315]. Although the scaffolds are very biocompatible and we have observed new bone in
direct contact with the scaffolds in vivo, more extensive new bone formation appears to
be prevented due to slow degradation of the scaffolds [13, 14]. We believe that the
osteogenic capacity of the scaffolds can be further enhanced by improving the
degradation profile of the scaffolds.
An important parameter of chitosan is degree of deacetylation (DDA), which is
defined as the ratio of deacetylated glucosamine units to the total number of monomers
[16, 17]. DDA has an effect on a number of chitosan properties, including crystallinity,
degradation, and mechanical strength. Since the lower number of acetyl residues allow
for tighter packing of the polymer chains, high DDA chitosan will be more crystalline
than lower DDA chitosan (if all other parameters are equal) [19, 24, 25]. High DDA
chitosan materials are more rigid and stronger than low DDA chitosan materials [26, 27],
but degrade more slowly [24, 27-30]. In previous studies, composite scaffolds were
prepared using 92.3% DDA chitosan [13-15]. This high DDA was chosen due to its good
mechanical properties. Using lower DDA chitosan to fabricate composite scaffolds may
result in increased degradation.
Our laboratory group has also demonstrated that increased surface area can be
obtained by freeze-drying (lyophilization) [15]. Increased surface area may promote
degradation by exposing more of the surface of the scaffolds to lysozyme and by
increasing fluid uptake. Chitosan is soluble in weak organic acids due to protonation of
the amine group on the glucosamine residues, and the pKa is approximately 6.5 [31].
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Washing composite microspheres in a mildly acidic solution before fusing them into
scaffolds was identified as another potential method to increase scaffold degradation.
Lower DDA chitosan, lyophilization, and a mild acid wash were evaluated for increased
degradation of composite scaffolds.
Although the main goal of this research is to improve the degradation profile of
the scaffolds to allow more extensive bone ingrowth, the other characteristics required of
bone scaffolds should still be met. The scaffolds need sufficient mechanical properties to
provide space maintenance at the fracture site and to prevent collapse of the scaffold
pores [8]. Maintaining porosity is vital so that cells can migrate to the interior of the
scaffold and so that proper nutrient/waste exchange can occur throughout the scaffold [7,
32, 33]. The scaffolds must provide a favorable surface for osteoblast attachment and
proliferation [8]. Chitosan-nano-hydroxyapatite composite scaffolds had previously been
shown to have both superior mechanical properties and induce more favorable cellular
responses compared to plain chitosan scaffolds [13, 14]. The addition of more
hydroxyapatite to the composite scaffolds could possibly improve the properties of the
scaffolds even more. In this research, fabrication parameters including chitosan DDA,
microsphere drying method, hydroxyapatite content, and the use of a mild acid wash
were investigated to fabricate composite chitosan-nano-hydroxyapatite scaffolds with
improved properties for bone regeneration.
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2. Experimental Section
2.1. Phase I: Effects of DDA and Drying Method
In Phase I of this research, the effects of DDA and drying method were evaluated.
Air-dried (A/D) and freeze-dried (F/D) 61% and 80% DDA scaffolds were prepared
(Figure 1).

61% DDA, A/D
61% DDA, F/D
80% DDA, A/D
80% DDA, F/D

80% DDA, A/D
selected as best
candidate

Phase I: DDA and drying

Tests
Degradation
Compression
Biocompatibility
Swelling Ratio

Optimized
Scaffold

Phase II: HA amount
and acid wash

Selected 80% DDA, A/D
3.0% CS, No HA
3.0% CS, 1x HA
2.5% CS, 2x HA
3.0% CS, 1x HA, Acid Wash

Figure 1. Experimental design used for scaffold characterization. Degradation of airdried and freeze-dried 61% and 80% DDA microspheres was also determined. All groups
underwent SEM analysis. A/D: air-dried; F/D: freeze-dried; CS: chitosan; HA:
hydroxyapatite.

2.1.1. Microsphere Fabrication
Composite chitosan-nano-hydroxyapatite microspheres were prepared using a coprecipitation method as previously described [13, 15]. Briefly, solutions containing 61%
DDA (MW = 220 kDa) or 80% DDA (MW = 260 kDa) chitosan (Primex, Siglufjordur,

35

Iceland), 0.1M CaCl2, and 0.06M NaH2PO4 (referred to as 1x HA, Ca:P ratio = 1.67)
were prepared in 2 volume percent (vol. %) acetic acid (Table 1).
Table 1. Chitosan solutions used to make composite beads. Note: Dissolved in 200 mL of
2 vol. % acetic acid. CS: Chitosan, HA: Hydroxyapatite.
Microsphere Type

Chitosan (g)

CaCl22H20 (g)

NaH2PO4 H20 (g)

61% DDA: 3.5% CS, 1x HA

7.00

2.94

1.66

80% DDA: 3.0% CS, 1x HA

6.00

2.94

1.66

A precipitation solution (pH = 13) containing 20 weight percent (wt. %) NaOH,
30 wt. % methanol, and 50 wt. % water was prepared. Using a syringe pump, the chitosan
solution was added dropwise through 16G needles into the precipitation solution, and
microspheres immediately formed. The microspheres were stirred in the precipitation
solution for 24 hours to allow crystalline hydroxyapatite to form. The microspheres were
then washed in deionized (DI) water until a neutral pH (<7.5) was achieved.
Microspheres were either air-dried (A/D) or freeze-dried (F/D). Air-drying was
performed by placing neutralized beads in plastic weigh boats and drying them in a
chemical fume hood at room temperature. Freeze-drying was performed by placing
neutralized (still hydrated) beads in plastic weigh boats and pre-freezing at −20 °C in a
laboratory freezer for two hours. The beads were then freeze-dried in a 2.5L Labconco
lyophilizer for 48 hours.
2.1.2. Scaffold Fabrication
Porous scaffolds were prepared by fusing dried microspheres together. The
microspheres were rinsed in 1wt. % acetic acid for approximately ten seconds in a
ceramic sieve. Excess acid was removed using a vacuum. This very brief acid wash
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gently dissolves the outer layer of the beads and makes them adherent. Using a laboratory
spatula, the microspheres were then placed in 12mm diameter polystyrene tubes to form
cylindrical scaffolds. Only very slight pressure was applied to the microspheres with the
spatula as they were placed in the polystyrene tubes. After approximately one minute, the
scaffolds were removed from the molds and allowed to air-dry. Following rehydration,
the scaffolds can be cut into any height as desired.
2.2. Phase II: Effects of Hydroxyapatite Content and MES Acid Wash
2.2.1 Microsphere and Scaffold Fabrication
Based on the data obtained in Phase I, air-dried 80% DDA scaffolds were
determined to be good candidates for bone regeneration. In Phase II, the following groups
of air-dried 80% DDA beads/scaffolds were prepared to determine the effect of
hydroxyapatite content and a mild acid wash: 3.0% CS, No HA; 3.0%, 1x HA; 2.5% CS,
2x HA; and 3.0% CS, 1x HA, acid wash. As seen in Table 2, No HA refers to solutions
containing only chitosan, and 2x HA denotes solutions with 0.2M CaCl2 and 0.12M
NaH2PO4 (Ca:P ratio = 1.67).
Table 2. Chitosan solutions used to make air-dried 80% DDA beads. Note: Dissolved in
200 mL of 2 vol. % acetic acid. CS: Chitosan, HA: Hydroxyapatite. *Also prepared using
MES acid wash.
Microsphere Type

Chitosan (g)

CaCl22H20 (g)

NaH2PO4 H20 (g)

3.0% CS, No HA

6.00

0.00

0.00

3.0% CS, 1x HA*

6.00

2.94

1.66

2.5% CS, 2x HA

5.00

5.88

3.31

In Phase II, all of the microspheres were air-dried. Scaffolds were prepared by the
method previously described.
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2.2.2. MES Acid Wash
Some of the 3.0% CS, 1x HA beads underwent a mild acid wash before being
air-dried (Table 2). A 40 mM 2-(N-morphilino)ethanesulfonic acid (MES) solution was
prepared, and the pH was raised to 6.1 using concentrated NaOH. Neutralized
microspheres (80% DDA, 3.0% CS, 1x HA) were added to the MES solution. The
microspheres were allowed to wash for ten minutes, and the pH was maintained at 6.1 by
adding additional MES powder. The microspheres were removed, washed in DI water,
washed in 70% and 95% ethanol, and placed in a chemical fume hood to dry. After
completely drying, the microspheres were then washed in 1x phosphate buffered saline
for thirty minutes and allowed to completely air-dry again. Scaffolds were prepared by
the method previously described.
2.3. Characterization
2.3.1. Scanning Electron Microscopy
Scanning electron micrograph (SEM) images of composite microspheres and
scaffolds were obtained using a Philips XL30 environmental microscope. Samples were
coated with 30nm of Au/Pd before imaging to make them conductive. Microsphere size
and surface topography were evaluated using SEM images.
2.3.2. Microsphere and Scaffold Degradation
Immediately prior to starting the degradation study, microsphere samples were
placed in a convection oven at 50 °C to mitigate the effects of ambient humidity. After
one hour, the microspheres were removed from the convection oven and weighed. An
amount of 4mL of degradation solution containing 100 μg/mL lysozyme (MP
Biomedicals, Cat. No. 100834) + antibiotics/antimycotic (1 unit/mL penicillin, 1 μg/mL
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streptomycin, and 0.25 μg/mL amphotericin B) in DI water was added to each sample.
Lysozyme is the main enzyme responsible for chitosan degradation in vivo [29, 34]. The
samples were placed in an incubator at 37 °C, and the degradation solution was refreshed
every three days. After one month, the microspheres were allowed to air-dry and were
then heated in a convection oven at 50 °C for one hour. The microspheres were weighed
and the percent weight change was determined using the following equation:

(Initial weight − final weight)/(Initial weight) × 100

(1)

Scaffold degradation was performed in the same manner as microsphere
degradation. Scaffolds were completely submerged in 6 mL of 100 μg/mL lysozyme +
antibiotics/antimycotic. After one month, the percent weight change was measured.
2.3.3. Compression Testing
The compressive moduli of scaffolds were determined using an Instron load
frame (Model # 33R 4465). Since the scaffolds will become hydrated after implantation,
they were rehydrated in DI water. 61% DDA scaffolds were rehydrated for four hours.
The interior beads of 80% DDA scaffolds were not completely hydrated after four hours,
so these scaffolds were rehydrated for eight hours. The diameter of the scaffolds varied
depending on the microsphere type, and the rehydrated scaffolds were sectioned so that
the height:diameter ratio was maintained at approximately 1.5. The scaffolds were then
compressed at a strain rate of 0.1 min−1 until 50% strain was achieved. The compressive
modulus was determined using the initial linear portion of the stress-strain curve.
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2.3.4. Swelling Ratio
The swelling ratio of scaffolds was determined. Pre-weighed scaffolds were
placed in 10 mL of deionized water and put in an incubator at 37 °C. After 24 hours, the
scaffolds were removed and pat-dried to remove any excess moisture on the surface. The
scaffolds were re-weighed and the swelling ratio was determined using the following
equation:
(Final weight − Initial weight) / (Initial weight) × 100

(2)

2.3.5. Biocompatibility
The biocompatibility of each microsphere type was evaluated using osteoblastlike SAOS-2 cells. Cells in McCoy’s 5A media supplemented with 15% fetal bovine
serum and antibiotics/antimycotic were seeded at a density of 2.2 × 105 cells/sample onto
microspheres in Transwell inserts in 24-well plates. The cells were incubated at 37 °C
with 5% CO2. After allowing cells to attach for three hours, the inserts were transferred to
empty wells, and cell attachment was evaluated using the CellTiter-Glo assay (Promega).
A standard curve relating luminescence output from the assay to cell number was
constructed by seeding cells at a known concentration. The remaining samples were
returned to the incubator after media refreshment, and cell numbers were determined on
Day 2 and Day 5.
2.4. Statistical Analysis
Mean ± standard deviations are presented. One-factor ANOVA with Bonferroni
post-test was performed to determine statistical differences, with p < 0.05 considered
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significant. Two-factor ANOVA with Bonferroni post-test was used to analyze the
biocompatibility data.
3. Results
3.1. SEM Images
Processing parameters were found to have an effect on microsphere properties
(Figures 2 and 3). Air-dried microspheres are smaller and spherical compared to freezedried microspheres which are larger and somewhat teardrop-shaped. Air-dried 61% DDA
beads have a very smooth surface; whereas, some cracks and surface roughness are
visible on air-dried 80% beads. Larger scale surface features are visible on both 61% and
80% DDA freeze-dried microspheres. When the amount of hydroxyapatite was increased,
the surface of the air-dried 80% DDA beads became considerably rougher. The MES acid
wash altered the shape of the beads. The edges of the acid-washed beads appeared
rounded due to slight dissolution; interestingly, the surface of these beads was
considerably smoother than that of 80% DDA beads which had not undergone the acid
wash. For all bead types, porous scaffolds were successfully prepared by fusing
microspheres together.
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Figure 2. SEM micrographs of air-dried (A/D) and freeze-dried (F/D) 61% and 80%
DDA microspheres and scaffolds. A: 61% DDA, 3.5% CS, 1x HA, A/D; B: 61% DDA,
3.5% CS, 1x HA, F/D; C: 80% DDA, 3.0% CS, 1x HA, A/D; D: 80% DDA, 3.0% CS, 1x
HA, F/D. 1: Microsphere at low magnification- 50x (A,C) and 30x (B,D); 2: Microsphere
at high magnification- 250x (A,C) and 100x (B,D); 3- Scaffolds at 30x magnification.
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Figure 3. SEM micrographs of air-dried 80% DDA microspheres and scaffolds. A: 3.0%
CS, No HA; B: 3.0% CS, 1x HA; C: 2.5% CS, 2x HA; D: 3.0% CS, 1x HA, MES acid
wash. 1: Microsphere at low magnification- 50x; 2: Microsphere at high magnification250x (A,B,D) and 100x (C); 3: Scaffolds at 30x magnification.

3.2. Microsphere Degradation
As seen in Figure 4, 61% DDA microspheres were found to degrade
approximately five times faster than 80% DDA microspheres. Freeze-drying minimally
increased the degradation of 61% DDA beads (p < 0.001) but did not increase the
degradation of 80% DDA beads (p = 0.70).
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Figure 4. Degradation of 61% DDA and 80% DDA microspheres. 61% DDA
microspheres are 3.5% CS, 1x HA. 80% DDA microspheres are 3.0% CS, 1x HA.
Statistical differences existed between all groups except 80% DDA air-dried and 80%
DDA freeze-dried beads. # represents no statistical difference. N = 3.

3.3. Phase I: Effects of DDA and Drying Method
Overall, the degradation rate of scaffolds was much lower than that of
microspheres (Table 3). Freeze-dried 61% DDA scaffolds had the highest degradation
with 3.5 ± 0.5% weight change after one month, which was statistically different from all
of the other groups (p < 0.001). The degradation rates of the other three scaffold groups
were statistically similar.
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Table 3. Degradation, compression testing, and swelling ratio of composite scaffolds. a:
Statistically different from all other groups. b: Statistically different from all other groups.
Degradation (%
Swelling Ratio
Compressive Modulus
Scaffold Type
wt. change)
(%)
(MPa) (N = 3)
(N = 4)
(N = 4)
61% DDA, A/D

1.4 ± 0.5

0.67 ± 0.06

148.3 ± 11.7 b

61% DDA, F/D

3.5 ± 0.5 a

0.12 ± 0.01

267.1 ± 15.3 b

80% DDA, A/D

1.3 ± 0.1

3.79 ± 0.51 a

88.5 ± 1.9 b

80% DDA, F/D

0.8 ± 0.3

0.81 ± 0.14

116.5 ± 6.9 b

Scaffolds composed of air-dried 80% DDA microspheres had the largest
compressive modulus (Table 3), which was statistically different from all of the other
groups (p < 0.001). None of the scaffolds fractured during compression testing. The 61%
DDA scaffolds had higher swelling ratios than the 80% DDA scaffolds, and freezedrying increased the swelling ratio (Table 2). Statistical differences in swelling ratio
existed between all of the groups.
Both air-dried and freeze-dried 61% and 80% DDA microspheres were found to
be biocompatible (Figure 5). Cell numbers increased at each timepoint. The only
statistically significant difference between the bead types was between 61% DDA freezedried beads and 80% DDA air-dried beads on Day 5 (p < 0.001).
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Figure 5. Biocompatibility of composite microspheres using SAOS-2 cells. * represents
statistical significance. N = 4.

3.4. Phase II: Effects of Hydroxyapatite Content and MES Acid Wash
Since all of the scaffold groups displayed similar biocompatibility and
degradation characteristics in Phase I, compression testing was used to select a candidate
for additional studies. Due to their considerably higher compressive modulus of 3.79 ±
0.51 MPa (Table 3), air-dried 80% DDA scaffolds with 3.0% CS, 1x HA were selected as
the most promising formulation for further enhancement. In Phase II, the effects of
hydroxyapatite content and an MES wash on air-dried 80% DDA scaffolds were
determined.
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Scaffolds composed of 3.0% CS, 1x HA were found to still have the highest
compressive modulus of all groups tested (Figure 6). However, this value was not
significantly different from scaffolds prepared with 2.5% CS, 2x HA, which had a value
of 3.04 ± 0.58 MPa (p = 0.535). A decrease in the compressive modulus to 1.57 ± 0.32
MPa was observed in the scaffolds prepared without hydroxyapatite (p<0.001). The
compressive moduli of 3.0% CS, 1x HA scaffolds which had undergone the mild acid
wash was significantly reduced to 1.76 ± 0.35 MPa (p < 0.001).

Figure 6. Compressive moduli of air-dried 80% DDA scaffolds. Scaffolds were
compressed at a strain rate of 0.1 min-1 until 50% strain was achieved. None of the
scaffolds fractured during testing. The compressive moduli were calculated from the
initial linear portion of the stress-strain curve. * represents statistical significance. #
represents no statistical difference. N = 3.
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Scaffolds undergoing the acid wash were found to have a degradation of 4.4 ±
0.4% after one month (Table 4), which was significantly higher than all of the other
groups (p < 0.001). The acid wash increased the swelling ratio of the scaffolds.
Increasing the hydroxyapatite content was found to decrease the swelling ratio.

Table 4. Degradation and swelling ratio of 80% DDA scaffolds. a: statistically different
from all other groups. b: statistically different from all other groups.
Degradation (% wt. change) Swelling Ratio (%)
Scaffold Type
(N = 4)
(N = 4)
3.0% CS, No HA

−0.3 ± 0.4 a

159.1 ± 1.9 b

3.0% CS, 1x HA

1.3 ± 0.1

88.5 ± 1.9 b

2.5% CS, 2x HA

1.7 ± 0.2

66.1 ± 0.9 b

3.0% CS, 1x HA, Acid Wash

4.4 ± 0.4 a

180.4 ± 3.3 b

All of the 80% DDA microsphere variations were found to be biocompatible
(Figure 7). No differences in attachment were found on Day 0. On Day 2, all of the
groups had statistically similar number of cells compared to Day 0, except for the No HA
group which had significantly more cells (p = 0.009). The No HA group had significantly
more cells than the 2x HA group (p = 0.001) and acid wash group (p = 0.010) on Day 2.
By Day 5, cell numbers had increased for all bead types compared to previous timepoints.
The No HA group had the most cells compared to the other groups, and the other three
groups were not statistically different.
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Figure 7. Biocompatibility of 80% DDA microspheres using SAOS-2 cells. * represents
statistical significance. # represents no statistical difference. N = 4.

4. Discussion
Composite chitosan-nano-hydroxyapatite microspheres were successfully
prepared using a co-precipitation method. SEM analysis revealed that fabrication
parameters had an effect on bead characteristics including size, shape, and surface
roughness. In addition, porous composite scaffolds composed of fused microspheres were
successfully fabricated. The degradation, mechanical, biocompatibility, and swelling ratio
properties of the modified microspheres and scaffolds were evaluated to determine the
best formulation for bone regeneration.
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4.1. Phase I: Effects of DDA and Drying Method
Interestingly, the concentration of chitosan that can be used to fabricate beads
successfully is within a narrow range. When the chitosan solution is dripped into the
precipitating solution, the chitosan solution cannot be too thick or too thin. If the chitosan
solution is too thick, long strands or very teardrop-shaped beads instead of spherical
microparticles will precipitate. In contrast, if the chitosan solution is too thin, small
fragments of chitosan will precipitate instead of microspheres. In these studies, 61%
DDA beads could only be prepared using a 3.5% chitosan solution due to the reasons
discussed above. When 80% DDA beads were prepared, a 3.5% chitosan solution
produced very elongated particles. However, spherical 80% DDA beads could be
fabricated when 3.0% and 2.5% chitosan solutions were used.
The increased degradation of 61% DDA microspheres compared to 80% DDA
microspheres was expected. Chitosan films, beads, and sponges have been shown to
degrade faster when prepared with lower DDA [24, 27-30]. Lim et al. observed the
weight half-lives of 52.6%, 56.1%, and 62.4% DDA chitosan beads to be 9.8, 27.3, and
56 days compared to weight half-lives of over 84 days for 71.7, 81.7, and 93.5% DDA
beads [29]. The fabrication method for preparation of these beads was not disclosed.
There is some debate about why high DDA chitosan degrades more slowly. Some
researchers have suggested that the crystalline nature of high DDA chitosan prevents
lysozyme from easily accessing the glycosidic bonds between the polymer chains,
resulting in slower degradation [19, 25]. Others researchers have suggested that the
binding site of lysozyme requires a certain number of acetylated residues to be present for
lysozyme to be able to degrade chitosan [28, 30].
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Since freeze-drying was previously shown to increase the surface area of
microspheres over 200× [15] and freeze-drying increased the swelling ratio, it is
somewhat surprising that freeze-drying only increased the degradation of 61% DDA
beads by less than two percent. Furthermore, scaffolds were observed to degrade more
slowly than microspheres. The freeze-dried 61% DDA scaffolds degraded the fastest but
only exhibited 3.5 ± 0.5% weight change over one month. Presumably, these differences
in degradation between beads and scaffolds are a surface area issue.
Mechanical properties are an important consideration for bone regeneration
constructs, and air-dried 80% DDA scaffolds were found to have the highest compressive
modulus. This is most likely due to their higher crystallinity and lower swelling ratio. It
should be noted that even though the 61% DDA scaffolds were rehydrated for only four
hours, they had lower compressive moduli than the 80% DDA scaffolds which had been
rehydrated for eight hours. Other researchers have also observed increased compressive
strength and modulus when using higher DDAs [26, 27]. The 3.79 ± 0.51 MPa
compressive moduli of the air-dried 80% DDA scaffolds is considerably higher than the
approximately 10 kPa or less moduli reported for many chitosan scaffold preparations
[10, 35, 36]. Furthermore, air-dried 80% DDA scaffolds had the best handleability.
Handleability refers to the ease with which we believe a surgeon could grab, manipulate,
and place the scaffold into a bone defect. For these reasons, we felt that air-dried 80%
DDA scaffolds held the most promise as bone tissue scaffolds of the formulations tested,
and the next phase of the investigation focused on further improving the air-dried 80%
DDA scaffolds.
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4.2. Phase II: Effects of Hydroxyapatite Content and MES Acid Wash
Other researchers have also observed that the addition of nano-hydroxyapatite
decreases the swelling ratio [10, 37] and increases the compressive moduli and strength
of chitosan scaffolds [10, 38]. However, addition of too much hydroxyapatite may have
negative effects. In the current study, the compressive modulus of air-dried 80% DDA
scaffolds with 3.0% CS, 1x HA (3.79 ± 0.51 MPa) was higher than that of both 3.0% CS,
No HA (1.57 ± 0.32 MPa) and 3.0% CS, 2x HA (2.51 ± 0.16 MPa, data not shown)
scaffolds. Similar to our results, Zhang et al. observed that increasing the hydroxyapatite
content of chitosan-nano-hydroxyapatite scaffolds improved compressive strength to a
point, but further increases in hydroxyapatite content decreased the compressive strength
[38]. In addition to altering structure at a molecular level, too much hydroxyapatite may
prevent the beads from being able to be fused together as soundly, resulting in poorer
mechanical properties. In fact, beads containing 4x HA could not even be fused together
into scaffolds (data not shown). Somewhat surprisingly, the compressive modulus of
scaffolds made with 2.5% CS, 2x HA beads was not significantly different from that of
3.0% CS, 1x HA. For this reason, air-dried 80% DDA scaffolds were prepared with 2.5%
CS, 2x HA instead of 3.0% CS, 2x HA during Phase II of the experiments.
In this study, plain 80% DDA microspheres without hydroxyapatite promoted
increased proliferation of SAOS-2 cells compared to composite microspheres with
hydroxyapatite. This result was unexpected, since we previously observed greater cell
proliferation on composite scaffolds compared to plain scaffolds [13, 14]. These previous
investigations were performed using human fetal osteoblast cells and human embryonic
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palatal mesenchymal stem cells. The SAOS-2 cells used in the current study may respond
differently to hydroxyapatite than the other cell types.
The MES acid wash was found to increase degradation of air-dried 80% DDA
scaffolds to 4.4 ± 0.4%. During the acid wash, the beads appeared to shrink slightly and
felt slightly “sticky”- suggesting mild dissolution. The degradation rate of acid-washed
scaffolds could potentially be increased even further by using a lower pH or increasing
the wash time. When compared to freeze-dried 61% DDA scaffolds, the 80% DDA acidwashed scaffolds had both higher degradation and compressive modulus.
Depending on the intended application, the properties of the chitosan-nanohydroxyapatite microspheres can be altered by changing the fabrication parameters as
demonstrated in this research. For application in bone tissue engineering, using a
combination of bead types to prepare scaffolds may be a promising approach. A
combination of fast-degrading 61% DDA freeze-dried beads or acid-washed beads could
be used in conjunction with slower-degrading but mechanically stronger 80% air-dried
beads. The fast-degrading beads could deliver a growth factor such as BMP-2 and then
degrade, increasing the available space for tissue ingrowth. The slower-degrading beads
would provide mechanical stability at the fracture site until new bone had developed and
then be resorbed more slowly. The ratio of beads types could be altered to give an
optimized scaffold for an intended musculoskeletal application.
5. Conclusions
Microspheres with 61% DDA had over 10% degradation after one month
compared to less than 2% for 80% DDA microspheres, and freeze-drying minimally
increased the degradation of 61% DDA microspheres. Scaffold degradation was found to
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be lower than microsphere degradation. The 3.8 ± 0.5 MPa compressive modulus of airdried 80% DDA scaffolds made them good potential candidates for bone regeneration.
Increases in hydroxyapatite content did not increase the compressive modulus of the 80%
air-dried scaffolds. A brief acid wash in an MES solution increased the degradation of
air-dried 80% DDA scaffolds. All of the composite microspheres tested demonstrated
good biocompatibility with SAOS-2 osteoblast-like cells. This study demonstrated the
ability to modify the functional properties of composite chitosan-nano-hydroxyapatite
scaffolds by altering the DDA, drying method, hydroxyapatite content, and using an MES
wash.
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Chapter 4 Fabrication of Crosslinked Carboxymethylchitosan Microspheres and
Their Incorporation Into Composite Scaffolds for Enhanced Bone Regeneration
INTRODUCTION
Although bone has a tremendous capacity to heal itself, approximately five to ten
percent of bone fractures will result in delayed healing or non-union.1 Bone grafting
procedures are commonly used to treat these fractures, but both autograft and allografts
are associated with a number of drawbacks.2-5 For this reason, our laboratories have
developed chitosan microspheres and scaffolds to augment fracture healing.6-9 The
microspheres are prepared using a precipitation method and are then adhered together
into scaffolds using an acid wash. These scaffolds are designed to provide a matrix to
which osteoblasts can attach and proliferate. Initially, the scaffolds will provide some
mechanical stability to the fracture site. As new bone is formed, ideally the scaffolds will
degrade to allow complete regeneration.10-12 These bone scaffolds can also be used as
local drug delivery vehicles to release growth factors such as bone morphogenetic
protein-2 (BMP-2) that will aid in the healing process.8,13-15
Our scaffolds have demonstrated potential in augmenting fracture healing.
However, the scaffolds have shown slow in vitro and in vivo degradation rates.6,7,9 If the
scaffolds do not degrade in a timely manner, new bone cannot fill the defect site and bone
regeneration will be impaired.16,17 We believe that our chitosan microbead scaffolds can
be improved by increasing the degradation rate of the constructs. Similar to many other
local BMP-2 delivery systems, our microspheres and scaffolds have previously
demonstrated a significant burst release of BMP-2 in which much of the growth factor is
released within the first few days.8 BMP-2 is involved in all stages of bone healing and
promotes recruitment of mesenchymal stem cells (MSCs) to the fracture site,
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angiogenesis, and differentiation of MSCs into osteoblasts.14,18-21 Recent studies have
demonstrated that an extended elution of BMP-2 is more effective at augmenting fracture
healing compared to a large burst effect alone.22-24
Chitosan is a versatile carbohydrate co-polymer of glucosamine and N-acetyl-Dglucosamine containing hydroxyl and amine groups that allow for numerous modification
strategies.25-27 One such strategy is the carboxymethylation of chitosan using
monochloroacetic acid.28-31 Carboxymethylchitosan (CMCS) is water-soluble and can be
crosslinked to form hydrogels. CMCS-based biomaterials crosslinked using 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) have demonstrated extensive degradation
capacity and good biocompatibility.29-35 EDC is a zero-length crosslinker that forms
amide bonds between carboxyl and amine groups.36-39 The natural crosslinker genipin,
which is derived from the Gardenia plant, has received attention recently due to its very
good biocompatibility compared to synthetic crosslinkers such as glutaraldehyde.40-42
Genipin is an amine-amine crosslinker, and genipin-crosslinked CMCS hydrogels have
also demonstrated potential use in biomedical applications.41,43-45 Most research using
EDC and genipin to prepare CMCS hydrogels has been performed in solution or on
highly porous constructs. Little research has been conducted on the feasibility of using
these chemicals to crosslink dense CMCS beads.
In addition to improved degradation, CMCS beads may also have improved BMP2 elution properties. The isoelectric point of BMP-2 is approximately 9.0, meaning that
BMP-2 will have a net-positive charge at neutral pH.46-48 The addition of a negativelycharged carboxyl group to chitosan may promote interaction between BMP-2 and the
material resulting in a more extended elution. The objective of these experiments is to
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fabricate EDC- and genipin-crosslinked CMCS microspheres and incorporate them into
our chitosan scaffolds. We hypothesize that the addition of CMCS beads to our scaffolds
will result in scaffolds with increased degradation and enhanced BMP-2 elution.
MATERIALS AND METHODS
Chitosan Microsphere Fabrication
Chitosan-nano-hydroxyapatite microspheres were prepared using a coprecipitation method as previously described.7,8 A solution containing 7.00g of 61%
DDA chitosan (Primex, Siglufjordur, Iceland), 0.10M CaCl2, and 0.06M NaH2PO4 (Ca:P
ratio = 1.67) was prepared in 200mL of 2 volume percent (vol. %) acetic acid. Using a
syringe pump, the chitosan solution was added dropwise through 16G needles into a
precipitation solution (pH=13) containing 20 weight percent (wt. %) sodium hydroxide
(NaOH), 30 wt. % methanol, and 50 wt. % water (H2O). Microspheres immediately
formed and were allowed to wash in the precipitation solution for 24 hours to allow
crystalline hydroxyapatite to form. The microspheres were then washed a few times with
deionized (DI) water and stored in DI H2O until carboxymethylation.
Carboxymethylation of Chitosan Microspheres
The chitosan microspheres were carboxymethylated using monochloroacetic acid
based on methods described by Chen and Park.28 A full batch of microspheres was added
to 200mL of an 80:20 isopropyl alcohol/water (IPA/H2O) mixture containing 30.00g of
sodium hydroxide. An amount of 30.00g of monochloroacetic acid (Fisher Scientific)
was dissolved in 40mL of isopropyl alcohol. After the beads had stirred for ten minutes in
the IPA/H2O mixture, the monochloroacetic acid solution was added dropwise. The beads
were stirred briskly and the reaction was allowed to proceed at 40o C. After four hours,
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the reaction was stopped by adding 400 mL of 70% ethanol (EtOH). The beads were then
washed in 70% EtOH and 95% EtOH. The carboxymethylchitosan (CMCS) beads were
dried overnight in a vacuum oven at 50oC.
Crosslinking of Carboxymethylchitosan Beads
Crosslinking was performed using carbodiimide chemistry to form amide bonds
between the amine and carboxyl groups of the CMCS beads.30 A solution containing
100mM 2-(N-morpholino)ethanesulfonic acid (MES), 20mM 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC; Thermo Scientific Prod. # 22980), and 50mM
N-hydroxysuccinimide (NHS; Thermo Scientific Prod. # 24500) was prepared in 300mL
of DI H2O. A full batch of CMCS beads was then added. The pH was adjusted to 6.5
using 1.0M hydrochloric acid (HCl). The beads were covered and the reaction proceeded
at room temperature. After 90 minutes, the beads were removed from the EDC/NHS
solution and were washed extensively with DI H2O followed by 70% EtOH. The
microspheres were then dried in a convection oven at 35oC. These beads will be referred
to as X-CMCS microspheres.
Crosslinking was also performed using the natural crosslinker genipin. A mixture
containing 300mL DI H20 and 50mL EtOH was prepared. An amount of 50mM MES and
5.7mM genipin (Wako Prod. #078-03021) were dissolved in the mixture. After waiting a
few minutes to allow dissolution of the genipin, a full batch of CMCS beads was added.
The pH was adjusted to and maintained at pH 7.4 using 6.0M HCl. The reaction was
allowed to proceed at room temperature for 8 hours. The beads were then removed from
the crosslinking solution and were washed extensively with DI H2O. The microspheres

61

were then dried in a convection oven at 35oC. These beads will be referred to as Gen-X
CMCS microspheres.
Microsphere Characterization
ATR-FTIR
Fourier transform infrared analysis was performed using a Nicolet iZ10
spectroscope (Thermo Scientific) with attenuated total reflectance. Powders of raw 61%
DDA chitosan flakes, 61% DDA chitosan microspheres, and uncrosslinked CMCS beads
were obtained by cooling the samples in liquid nitrogen followed by grinding with a
mortar and pestle. Transmission spectra were recorded in the range of 4000-500 cm-1
using thirty-two scans with 4 cm-1 resolution.
Ninhydrin Assay
Crosslinking was verified by determining the number of free amine groups in the
microspheres using a ninhydrin assay.49 A solution containing 1.15g of citric acid
monohydrate and 40.0mg of stannous chloride dihydrate in 15mL of DI H2O and 10mL
of 1.0M NaOH was prepared (Solution A). A solution containing 1.00g of ninhydrin
(Acros Organics) in 25mL of ethylene glycol monomethyl ether was also prepared
(Solution B). Solutions A and B were mixed together and stirred for 45 minutes covered
by aluminum foil to protect from light. Approximately, 5 mg of microspheres (n=4) were
weighed and placed in Pyrex test tubes containing 100µL of DI H2O. Standards
containing 5, 4, 3, 2, 1, and 0 μmole/mL glycine were prepared in DI H2O with a total
volume of 100µL. An amount of 1mL of ninhydrin solution was added to all samples.
The samples were placed in a water bath at 100oC and monitored for development of
purple color. After eight minutes, the samples were removed from the water bath and
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5mL of 50% IPA was added to each sample. The samples were transferred to a 96-well
plate after being vortexed, and the absorbance of 100uL of each sample was read in
triplicate at 570nm.
Swelling Ratio
The swelling ratio of microspheres (n=3) was determined by placing pre-weighed
microspheres in 3mL of 1x phosphate buffered saline (PBS) in 12-well plates. The
samples were covered and placed in an incubator at 37oC. After 24 hours, the samples
were pat-dried to remove excess PBS and re-weighed. The swelling ratio of the
microspheres was determined by the following:
(Final weight – initial weight) / (Initial weight) * 100%.

Degradation
The degradation profile of microspheres was determined in 1x PBS and lysozyme.
Lysozyme is the main enzyme responsible for chitosan degradation in vivo.50,51 Preweighed microspheres (n=4) were placed in 4mL of 1x PBS containing
antibiotics/antimycotic (AB/AM; 1 unit/mL penicillin, 1μg/mL streptomycin, and
0.25μg/mL amphotericin B; MP Biomedicals Cat. No. 1674049) or 1x PBS containing
AB/AM and 100μg/mL lysozyme (MP Biomedicals, Cat. # 100834). Samples were
incubated at 37oC, and the degradation solutions were refreshed every three days. After
fifteen days or thirty days, the microspheres were removed from the degradation solution,
dried, and re-weighed. The percent weight change was determined using the following
equation:
(Initial weight – final weight) / (Initial weight) * 100%.
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rhBMP-2 Elution
Approximately, 200 mg of beads (n=4) were weighed and placed in small glass
scintillation vials. The beads were loaded overnight at room temperature with 4mL of a
5μg/mL rhBMP-2 (Medtronic, Inc.) solution in 1xPBS. On the following day, the BMP-2
loading solution was aspirated and 4mL of elution buffer (1x PBS containing AB/AM
and 0.01% bovine serum albumin (BSA)) was added to each vial. Elution samples were
obtained on days 1, 3, 6, 10, 15, 21, 28, 36, and 45 by removing a 1mL eluate. The
remaining solution was aspirated, and 4mL of fresh elution buffer was added at each
timepoint. Elution samples were stored in low retention microcentrifuge tubes at -80oC.
The amount of rhBMP-2 eluted was determined using an ELISA kit (PeproTech, Inc.)
according to the manufacturer’s instructions.
Scaffold Fabrication
Composite scaffolds containing crosslinked CMCS beads and 80% DDA chitosan
(CS) beads were prepared. Firstly, 80% DDA microspheres were fabricated as previously
described by dissolving 6.00g of chitosan in 200mL of 2 vol. % acetic acid. Following
precipitation in the basic solution, the beads were washed in DI H2O until the pH was less
than 8.0. The 80% DDA CS beads were then allowed to air-dry at room temperature.
Porous scaffolds were prepared by fusing dried microspheres together. The
microspheres were rinsed in 1 vol. % acetic acid for approximately ten seconds in a
porcelain Buchner funnel (CoorsTek Prod. # 60243). Excess acid was removed using a
vacuum. The microspheres were placed in 12mm diameter polystyrene tubes. After
approximately one minute, the scaffolds were removed from the molds and allowed to
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air-dry. When rehydrated, scaffolds can be cut to any height as desired using a razor
blade.
The following three groups were prepared: 80% DDA CS-only scaffolds,
composite X-CMCS/CS scaffolds, and composite Gen-X CMCS/CS scaffolds. The
composite scaffolds contained a ratio of approximately 2:1 CS to CMCS beads. Before
performing the acid wash, lines were drawn on the polystyrene tubes at 15mm and 45mm
from the bottom of the tubes. CMCS beads were added to the first line, and 80% DDA
CS beads were added until the second line was reached. The beads were then placed in
the Buchner funnel for the acid wash.
Scaffold Characterization
Scaffold Compression, Degradation, and BMP-2 Elution
Compression testing of hydrated scaffolds (n=3) was performed as previously
reported.52 Scaffold degradation (n=4) was determined in 6mL of 100μg/mL lysozyme
solution at thirty days in the same manner as microsphere degradation. The elution of
rhBMP-2 from the scaffolds (n=4) was also determined in a manner similar to bead
elution. The scaffolds were loaded with 6mL of 5μg/mL rhBMP-2 solution, and the
rhBMP-2 was eluted into a volume of 6mL. As before, rhBMP-2 eluate concentrations
were determined using ELISAs.
rhBMP-2 Activity Determination
In order to determine the bioactivity of the rhBMP-2 eluted from the scaffolds, an
additional 1mL eluate was obtained at each timepoint. The activity of the released
rhBMP-2 was determined by alkaline phosphatase (ALP) induction in W20-17 mouse
stromal cells (ATCC® Number CRL-2623™) based on ASTM standard F2131.53 In a 96-
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well plate, 200µL of 5x104 cells/mL suspension in complete media (Thermo Scientific
HyClone® DMEM/High Glucose media containing 10% standard fetal bovine serum
(FBS; Thermo Scientific HyClone®) and AB/AM) was added to each well. The cells were
allowed to attach overnight in an incubator at 37oC with 5% CO2 and 100% humidity. On
the following day, the complete media was aspirated from the wells, and the wells were
washed with 1x PBS. An amount of 180μL of fresh media without FBS and 20μL of
rhBMP-2 sample were added to each well. Sample dilutions were prepared in elution
buffer as needed. A standard curve was prepared by adding 20μL of the following
rhBMP-2 solutions (in elution buffer) to 180μL of fresh media: 10000, 5000, 2500, 1250,
625, 313, 156, 78, 39, 20 and 0ng/mL. The plates were returned to the incubator.
After 24 hours, the amount of ALP produced by the cells was determined. Media
was aspirated from the wells, and 80μL of microbiology-grade H2O was added to each
well. After the cells had lysed, two freeze-thaw cycles were performed. An amount of
20μL of 0.5M alkaline buffer (Sigma-Aldrich Prod. # A9266) and 100μL of 5mM 4nitrophenyl (Sigma-Aldrich Prod. # P4744) solution were added to the wells. The plates
were returned to the incubator for fifty minutes. An amount of 100μL of 0.3M NaOH was
added to stop the reaction, and the absorbance of each well was determined at 405nm.
SAOS-2 Cell Proliferation
The cytocompatibility of the composite scaffolds was demonstrated using SAOS2 osteosarcoma cells (ATCC® Number HTB-85™). The scaffolds (n=4) were placed in
24-well plates and soaked in 70% EtOH for two hours. The scaffolds were washed in 1x
PBS three times and transferred to new plates. An amount of 1mL of media (Thermo
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Scientific HyClone® McCoy’s 5A media containing 15% FBS and AB/AM) was added to
each well, and the scaffolds were placed in an incubator overnight.
On the following day, the media was aspirated. The scaffolds were then seeded
with SAOS-2 cells in 1mL of media at a density of 2x105 cells/well. After three hours,
the scaffolds were transferred to empty wells and the number of cells attached (Day 0)
was determined using the CellTiter-Glo® assay (Promega). A standard curve relating
relative luminescence units to cell number was obtained by plating a known amount of
cells. The remaining scaffolds were transferred to new wells with fresh media. Cell
numbers were determined on Days 2 and 6 using CellTiter-Glo®. On Day 6,
LIVE/DEAD® staining was also performed. Amounts of 20μL of calcein (Invitrogen
Prod. # C3099) and 20μL of ethidium bromide (Invitrogen Prod. # L3224) were added to
10mL of 1xPBS. Then, 1mL of this solution was added to each scaffold, and cells were
viewed using a fluorescent microscope equipped with BioQuant imaging software.
Scanning Electron Microscopy and Photograph Imaging
Scanning electron micrograph (SEM) images of microspheres and scaffolds were
obtained using a Philips XL30 environmental microscope. Samples were coated with
30nm of Au/Pd before imaging to make them conductive. Photographs of beads and
scaffolds were also obtained using a Nikon Coolpix 5400 digital camera.
Statistics
Data are presented as mean ± standard deviation. Statistics were performed using
an appropriate ANOVA method with p<0.05 considered significant. Kruskal-Wallis
analysis was used when data was not normal or unequal variances were detected.
Pairwise comparisons were obtained using the Student-Neuman-Keuls (SNK) test.
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RESULTS
CMCS microspheres were successfully prepared as seen in Figure 1. The Gen-X
CMCS beads have a distinctive dark green color to them, and the X-CMCS beads are
deep golden in color (see online for full color images). All of the microspheres are similar
in size with a diameter of roughly 1mm, and the beads have a slight tear-drop shape. Both
the Gen-X CMCS and X-CMCS beads have a more textured surface compared to the
smoother 61% DDA CS beads. The CMCS beads were successfully incorporated into
porous composite scaffolds (Figure 2).

Figure 1. Digital photographs and SEM micrographs of microspheres. Top row (L-R):
61% DDA CS bead, Gen-X CMCS bead, and X-CMCS bead photographs; Bottom row
(L-R): 61% DDA CS bead, Gen-X CMCS bead, and X-CMCS bead micrographs at 50x
magnification (scale bar is 500µm).
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Figure 2. Digital photographs and SEM micrographs of scaffolds. Top row (L-R): 80%
DDA CS-only scaffold, composite Gen-X CMCS/CS scaffold, and composite XCMCS/CS scaffold photographs; Bottom row (L-R): 80% DDA CS-only scaffold,
composite Gen-X CMCS/CS scaffold, and composite X-CMCS/CS scaffold micrographs
at 25x magnification (scale bar is 1,000µm).

Microsphere Characterization
The FTIR spectra demonstrated that carboxymethylation of the chitosan beads
had occurred (Figure 3). The 61% DDA powder and 61% DDA bead spectra display the
characteristic peaks of chitosan.28,54 The bands at 1591 cm-1 and 1416 cm-1 on the CMCS
spectrum denote a carboxyl group and confirm that the carboxymethylation reaction was
successful.33,54,55
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Figure 3. ATR-FTIR spectra of chitosan and CMCS. A) 61% DDA chitosan powder; B)
61% DDA chitosan beads; and C) CMCS beads. * represents peaks characteristic of
carboxyl groups.

Crosslinking of the CMCS beads was confirmed by the ninhydrin assay. A
reduction in the number of free amine groups was observed for the Gen-X CMCS
(p=0.015) and X-CMCS (p=0.003) beads (Table 1). Although the number of free amine
groups remaining after crosslinking was lower in the X-CMCS beads compared to the
Gen-X CMCS beads, this difference was not significant (p=0.061).
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Table 1. Free amine groups and swelling ratio of beads. * represents statistical difference
from all other groups. # represents no statistical difference between groups.
Swelling Ratio (%)
Bead Type
µmole amine/g beads
61% DDA CS
176.3 ± 18.1*
44.4 ± 7.9*
Gen-X CMCS

32.0 ± 4.3#

398.1 ± 8.1*

X-CMCS

22.6 ± 2.5#

612.1 ± 3.2*

The CMCS beads demonstrated increased swelling properties in 1x PBS
compared to the 61% DDA CS microspheres (Table 1). The swelling ratio of the Gen-X
CMCS beads increased to around 400%; whereas, the swelling ratio of the X-CMCS
increased to over 600%.
The microsphere groups demonstrated very different degradation properties
(Table 2). The CS beads displayed slight degradation in lysozyme, but gained weight in
PBS. The Gen-X CMCS beads displayed roughly 23% degradation for all conditions. The
X-CMCS beads displayed approximately 10% weight loss after thirty days in PBS;
whereas; the X-CMCS beads were almost completely degraded after thirty days in the
lysozyme solution.

Table 2. Degradation of microspheres. Negative values indicate weight gain. Statistics
performed using two-factor ANOVA with SNK post-hoc test for each buffer condition.*
and & represent statistical difference from all other groups at timepoint. a, b, and c
represent statistical difference between timepoints.
1x PBS
100μg/mL lysozyme
Bead Type
Fifteen Days
Thirty Days
Fifteen Days
Thirty Days
(% Weight
(% Weight
(% Weight
(% Weight
Change)
Change)
Change)
Change)
61% DDA CS

-1.8 ± 0.5 *

-2.4 ± 0.2*

4.1 ± 0.1&,b

8.4 ± 0.8&,b

Gen-X CMCS

23.3 ± 0.5*

22.6 ± 1.1*

23.3 ± 0.7&

23.6 ± 0.3&

X-CMCS

8.7 ± 1.1*,a

10.1 ± 1.2*,a

54.4 ± 2.4&,c

82.7± 1.2&,c
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The 61% DDA CS and X-CMCS beads both displayed a moderate burst release of
BMP-2 followed by extended elution (Figure 4). The Gen-X CMCS beads eluted very
little BMP-2 over the course of the study.

Figure 4. rhBMP-2 elution from microspheres. Gen-X CMCS microspheres were
significantly different from both other groups at all timepoints. * represents statistical
difference between 61% DDA chitosan and X-CMCS microspheres.

Scaffold Characterization
Although the compressive moduli of the composite scaffolds were slightly lower
than that of the CS-only scaffold (Table 3), the differences were not significant
(p=0.050).
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Table 3. Scaffold compression and degradation. * represents statistical difference from
all other groups. # represents no statistical difference between groups.
Scaffold Type
Compressive Modulus
Thirty Day Degradation
(MPa)
(% Weight Change)
80% DDA CS
1.6 ± 0.3#
0.5 ± 0.4*
Gen-X CMCS/CS

1.0 ± 0.1#

-2.7 ± 0.3*

X-CMCS/CS

1.4 ± 0.1#

14.5 ± 6.6*

Scaffold degradation was increased by the addition of X-CMCS microspheres
(Table 3). CS-only scaffolds displayed minimal degradation, and Gen-X CMCS/CS
scaffolds gained weight during the study. After four weeks, the mass of the composite XCMCS/CS scaffolds had decreased over fourteen percent.
The elution of rhBMP-2 from scaffolds was improved by the addition of XCMCS beads (Figure 5). The X-CMCS/CS scaffolds released more rhBMP-2 at all
timepoints compared to the CS-only and Gen-X CMCS/CS scaffolds. The CS-only
scaffolds and Gen-X CMCS/CS scaffolds had very similar release profiles that were
statistically different only on days 10 and 15.
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Figure 5. rhBMP-2 elution from scaffolds. X-CMCS/CS scaffolds released more BMP-2
on all days. * represent statistical difference between Gen-X CMCS/CS and CS-only
scaffolds.

All of the rhBMP-2 eluates were determined to be bioactive as shown by their
ability to induce alkaline phosphatase production in W20-17 mouse stromal cells (Figure
6). The shape of the release profiles obtained using the W20-17 assay to measure active
BMP-2 was similar to those obtained using ELISAs. As before, composite X-CMCS/CS
scaffolds released statistically significant higher levels of growth factor on all days.
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Figure 6. Amount of active rhBMP-2 in scaffold eluates as determined by W20-17 assay.
X-CMCS/CS scaffolds released more active BMP-2 on all days. No statistical differences
exist between Gen-X CMCS/CS and CS-only scaffolds.
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The composite scaffolds promoted the attachment and proliferation of SAOS-2
cells in this study (Figure 7).

Figure 7. SAOS-2 attachment and proliferation on chitosan scaffolds. * represents
statistical significance from other groups.

However, the Gen-X CMCS/CS scaffolds had fewer cells on Day 2 compared to the other
groups, and the CS-only scaffolds had more cells on Day 6. Very few dead cells were
observed on the scaffolds using Live/Dead staining (Figure 8). Cells spread very well on
the X-CMCS/CS and CS scaffolds and displayed an elongated morphology; whereas, the
SAOS-2 cells had a rounded morphology on the Gen-X CMCS/CS scaffolds and did not
spread as well.
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Figure 8. Live/Dead staining of SAOS-2 cells on scaffolds on Day 6. Original
magnification of 4x. L-R: 80% DDA CS-only scaffold, Gen-X CMCS/CS scaffold, and
X-CMCS/CS scaffold.

DISCUSSION
CMCS beads were fabricated by carboxymethylation of CS microspheres using
monochloroacetic acid. The reaction conditions were selected based on previous
optimization experiments.28 Chen and Park previously demonstrated that an IPA:H2O
ratio of 80:20 and reaction temperature of 40oC will result in a high degree of
carboxymethylation.28 Our data shows that this reaction scheme can be used to
successfully perform carboxymethylation of dense microspheres.
Genipin-crosslinking of CMCS beads was successful but occurs somewhat slowly
as evidenced by the eight hours required for sufficient crosslinking. Shorter reaction
times resulted in beads in which the outside of the microspheres would crack when the
beads were subjected to swelling evaluations in aqueous solutions. The reaction was
performed at room temperature and at neutral pH, since these conditions result in high
degrees of crosslinking.41,56 The 5.7mM (0.13% w/v) genipin concentration used is
similar to those previously employed to crosslink chitosan-based materials.41,43,49,56
Similar to other researchers, our experiments suggest that genipin-crosslinking
can result in the outer layers of a material being thoroughly crosslinked while the interior
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of the material experiences limited crosslinking.42,49,56 This hypothesis is supported by the
previously described cracking of insufficiently crosslinked microspheres and the
degradation profile of the Gen-X CMCS beads. The roughly 23% weight loss displayed
by all of the Gen-X CMCS microsphere groups was not enzyme or time-dependent. This
weight loss was likely due to very fast dissolution of insufficiently crosslinked CMCS in
the interior of the beads, but the remaining crosslinked material was highly stable and did
not degrade. In fact, evidence suggests that genipin may sterically hinder lysozyme from
accessing the glycosidic bonds of genipin-crosslinked chitosan.40,41
Crosslinking proceeded more quickly using EDC/NHS. X-CMCS degradation
was found to be primarily enzymatic and not due to hydrolysis. The increase in
enzymatic degradation (over 80% after thirty days) is likely related to the crystallinity of
the X-CMCS beads. Abreu et al. reported that carboxymethylation of chitosan altered the
arrangement of polymer chains resulting in lower crystallinity.57 Furthermore,
Guangyuan et al. demonstrated the loss of crystallinity that occurs after EDC crosslinking
in CMCS films.29 Presumably, the reduced crystallinity of the X-CMCS beads allows
lysozyme easier access to the glycosidic bonds between the chitosan monomers. Similar
to our results, Wang et al. observed a 70% reduction in the mass of
carboxymethylchitosan scaffold tubes after eight weeks in a lysozyme solution, compared
to only 4.3 ± 3.6% weight loss of chitosan scaffold tubes.31
Crosslinking method was found to have a large impact on BMP-2 release from the
microspheres. The Gen-X CMCS beads released little BMP-2 over the course of the
study; whereas, the X-CMCS and 61% DDA CS microspheres both demonstrated a
tempered burst release followed by extended elution of BMP-2. Even at Day 45,
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considerable amounts of BMP-2 were still being released from these groups. In a criticalsize rat femoral defect, Brown et al. demonstrated that a burst release of BMP-2 followed
by sustained elution is more effective than a burst release only or even sustained elution
without a burst.22 The X-CMCS and 61% DDA beads both demonstrated this efficacious
release profile. Our data suggests that DDA can be used to modify the release of BMP-2
from chitosan. In this study, 80% DDA chitosan displayed a larger initial burst release of
BMP-2 compared to 61% DDA chitosan, and we have previously observed a large burst
release from 92.3% DDA chitosan microspheres.8 Thus, chitosan with a lower DDA
seems to promote a smaller burst release and more extended elution compared to higher
DDAs. Although the X-CMCS beads were not able to further enhance the growth factor
release, these microspheres are better suited than CS beads for applications such as bone
regeneration in which both growth factor release and degradability is desired.
X-CMCS and Gen-X CMCS beads were successfully incorporated into composite
chitosan scaffolds. The slight dissolution of chitosan beads in the 1% acetic acid wash
due to protonation of the amine group makes the chitosan beads adherent and allows the
microspheres to be fused into scaffolds. Due to the significant loss of amine groups
caused by crosslinking, X-CMCS and Gen-X CMCS beads do not become adherent in the
acid wash. As found in these evaluations, the crosslinked beads can only be fused into
scaffolds when a sufficient amount of CS beads are present. The smallest ratio of
CS:CMCS beads that could be used to fabricate scaffolds that stayed together was 2:1.
80% DDA microspheres without hydroxyapatite were chosen as the CS bead component
due to their good mechanical properties and cytocompatibility as previously reported.52
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The incorporation of X-CMCS beads into composite scaffolds improved the
degradation and drug delivery properties of the scaffolds. The 14.5 ± 6.6% weight loss of
the X-CMCS/CS scaffolds after thirty days is much higher than the 0.5 ± 0.4% weight
loss of the CS-only scaffolds. This increased degradation is expected to promote better
osteoblast penetration into the scaffolds resulting in more extensive bone regeneration.
The X-CMCS/CS composite scaffolds released more rhBMP-2 at all timepoints and are
expected to promote increased osteogenesis. Furthermore, the BMP-2 eluted was shown
to be active by its ability to increase ALP production in W20-17 mouse stromal cells. If
more X-CMCS beads could be incorporated into the composite scaffolds, the amount of
degradation and BMP-2 eluted would likely increase even more.
The X-CMCS/CS composite scaffolds demonstrated good cytocompatibility with
SAOS-2 cells in this study. EDC-crosslinked CMCS materials have previously shown the
ability to support attachment and proliferation of a number of cell types including
osteoblasts and MSCs.29-31,33,34 Cai et al. demonstrated enhanced proliferation and
increased ALP production of rat calvarial cells cultured on PDLLA films containing
CMCS and crosslinked with EDC.32 Although the Gen-X CMCS/CS scaffolds appeared
to be cytocompatible, SAOS-2 proliferation was slower on this group and these cells
displayed atypical morphology. Wang et al. recently published experiments suggesting
that genipin exhibits a dose-dependent toxicity with human fetal osteoblast cells and that
exposure of cells to genipin should be kept less than 0.5mM.58 A concentration of 5.7mM
genipin was used to crosslink the microspheres, and residual genipin could be responsible
for the decreased proliferation and atypical morphology.
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CONCLUSIONS
CMCS beads were produced by the carboxymethylation of chitosan microspheres
using monochloroacetic acid. The crosslinking agent was found to have a large impact on
the properties of the beads. Genipin-crosslinked microspheres displayed an undesirable
degradation profile, and Gen-X CMCS beads released very little rhBMP-2. EDCcrosslinked beads demonstrated increased enzymatic degradation of 82.7 ± 1.2% after
thirty days. The X-CMCS beads demonstrated a tempered burst release followed by an
extended elution of growth factor. Composite scaffolds containing X-CMCS
microspheres had improved degradation and drug release properties. These scaffolds
were found to be cytocompatible with SAOS-2 cells and are expected to promote
enhanced bone regeneration. Future studies will evaluate the ability of composite XCMCS/CS scaffolds to augment fracture healing in vivo.
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Chapter 5 Additional Characterization of Composite Scaffolds
1. Porosity Determination
The porosity of scaffolds was determined using a liquid displacement method
based on Archimedes’ principle [86]. The following three groups of scaffolds were
prepared as described in Chapter 4: CS, composite Gen-X CMCS/CS, and composite XCMCS/CS scaffolds. The height (H) and diameter (D) of the scaffolds was measured
using calipers. The components of a density determination kit (Mettler Toledo,
Switzerland) were assembled according to the manufacturers’ instructions. Methanol was
placed in a beaker, and the wire basket was submerged in the liquid. The balance was
tared, and a scaffold was placed in the upper cup holder. The mass of the dry scaffold
was recorded as A. The balance was tared again, and the scaffold was placed in the
beaker of methanol. Air bubbles were removed from the scaffold by placing the beaker in
a vacuum oven (Fisher Scientific, Isotemp® Model 285A) at 15 inches Hg gauge for five
minutes. The density kit was reassembled, and the scaffold was placed in the submerged
wire basket. This mass was recorded as P. The density of the scaffold was determined
using the following equation:

,

where ρmethanol is the density of methanol. The total volume of the cylindrical scaffold was
calculated by the following:

.
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The volume of the scaffold without pores was determined using the following equation:

.

The porosity was then calculated by the following:

The composite scaffolds had higher porosities that the CS-only scaffolds (Table
1).

Table 1. Scaffold porosity. Statistics performed using one-way ANOVA with SNK posthoc test. p-values less than 0.05 considered statistically significant. * represents statistical
difference from all other groups.
Scaffold Type
Porosity (%)
80% DDA CS

35.5 ± 2.1*

Gen-X CMCS/CS

41.1 ± 2.2*

X-CMCS/CS

44.3 ± 1.5*

In addition, the X-CMCS/CS composites had a slightly higher porosity than the Gen-X
CMCS/CS scaffolds. Presumably, the slightly different shape and size of the Gen-X
CMCS and X-CMCS beads resulted in less-tight microsphere packing during scaffold
fabrication which resulted in slightly higher porosity (Figure 1).
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Figure 1. SEM micrographs of chitosan microspheres and scaffolds. Top row (L-R): 61%
DDA CS bead, Gen-X CMCS bead, and X-CMCS bead micrographs at 50x
magnification (scale bar is 500µm). Bottom row (L-R): 80% DDA CS-only scaffold,
composite Gen-X CMCS/CS scaffold, and composite X-CMCS/CS scaffold micrographs
at 25x magnification (scale bar is 1,000µm).

Porosity is a very important characteristic of tissue engineered scaffolds. Porosity
must be adequate enough to promote good nutrient and waste exchange to and from the
scaffold [1, 60, 87, 88]. It has been suggested that a minimum porosity of thirty percent is
needed for bone scaffolds to promote osteogenesis [89]. Thus, the CS-only scaffolds
barely meet the minimum requirement. The additional porosity obtained by the
incorporation of the CMCS beads should be beneficial and is expected to promote
increased fluid exchange and tissue ingrowth. In addition, the compressive moduli of the
X-CMCS/CS and Gen-X CMCS/CS scaffolds (Table 2) did not decrease during
compression testing (p=0.061). Since an increase in porosity can result in poorer
mechanical properties, a compromise between mechanical stability and porosity is
required [60]. Indeed, the composite scaffolds displayed increased porosity while
maintaining good mechanical characteristics.
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Table 2. Compressive moduli of scaffolds. Statistics performed using Kruskal-Wallis
with p-value less than 0.05 considered statistically significant. # represents no statistical
difference between groups.
Scaffold Type
Compressive Modulus
(MPa)
80% DDA CS
1.6 ± 0.3#
Gen-X CMCS/CS

1.0 ± 0.1#

X-CMCS/CS

1.4 ± 0.1#
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Chapter 6 Conclusions
The rat muscle pouch osteoinductivity study in Chapter 2 demonstrated the need
for increased scaffold degradation. Although the scaffolds demonstrated good
biocompatibility, little to no degradation was observed in vivo after one month. Very
little (less than 2% of the defect area) contained new bone. In contrast, the BMP-2 loaded
collagen sponge used as a positive control had completely degraded after one month and
extensive osteogenesis was observed. This in vivo model demonstrated the potential of
our scaffolds for use in bone regeneration but reaffirmed the need for increased
degradation.
The selection of the chitosan bead component of the composite scaffolds was
described in Chapter 3. The effects of DDA, drying method, and hydroxyapatite content
on biocompatibility, degradation, compressive properties, and swelling ratio were
investigated. All of the scaffolds demonstrated minimal degradation. 80% DDA scaffolds
had higher compressive moduli compared to 60% DDA scaffolds. Interestingly, scaffolds
without hydroxyapatite were found to have better cytocompatibility with SAOS-2 cells
compared to scaffolds containing hydroxyapatite. For this reason, air-dried 80% DDA
microspheres without hydroxyapatite were chosen as the chitosan bead component of the
composite scaffolds due to their excellent cytocompatibility and good mechanical
properties (compressive modulus of 1.6 ± 0.3 MPa).
The fabrication of CMCS microspheres and the different properties obtained
using genipin and EDC as crosslinking agents was described in Chapter 4. Gen-X CMCS
microspheres had poor degradation properties and released very little BMP-2 during the
elution study. In contrast, the X-CMCS microspheres degraded over eighty percent in one
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month and demonstrated an extended BMP-2 elution profile. The incorporation of XCMCS beads into composite scaffolds improved the properties of the constructs. The
degradation of composite X-CMCS/CS scaffolds increased to 14.5 ± 6.6% compared to
0.5 ± 0.4% for CS-only scaffolds. The X-CMCS/CS scaffolds released more BMP-2 at all
timepoints. These composite scaffolds also displayed good cytocompatibility with SAOS2 cells, and their compressive modulus (1.4 ± 0.1 MPa) was not decreased by the
inclusion of X-CMCS beads. Thus, our hypothesis was confirmed.
These experiments demonstrated the benefit of using a composite approach when
designing biomaterial technologies for bone regeneration. Due to the numerous
characteristics required of a bone tissue scaffold including cytocompatibility,
degradability, and mechanical stability, very few materials can meet these demands
alone. In many cases, a composite approach incorporating multiple materials into a
construct may be beneficial. Indeed, our chitosan bone regeneration technology was
improved by the addition of X-CMCS beads into the constructs to form composite
scaffolds. The X-CMCS/CS composite scaffolds showed increased potential for
augmentation of bone healing and improved outcomes for severe fractures.
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Chapter 7 Recommendations for Future Work
The ability of the X-CMCS/CS scaffolds to promote bone regeneration should be
assessed in an animal model in vivo. Preferably, the constructs should be evaluated in a
critical-sized segmental bone defect. The X-CMCS/CS composites can potentially be
further enhanced in a number of ways. The reaction conditions for both the
carboxymethylation and EDC-crosslinking steps can be optimized to yield microspheres
with the most desirable properties. Both of these reactions depend on a number of
parameters and a high degree of tailorability should be possible. Methods for
incorporating more X-CMCS beads into the composite scaffolds should be pursued. The
current scaffold fabrication process limits the amount of X-CMCS beads that can be
incorporated, and the benefits of X-CMCS addition were not fully realized. Use of the XCMCS beads in other composite strategies should also be considered. For instance, a
composite containing X-CMCS beads embedded in calcium phosphate cement could be
useful as a bone graft substitute. The mechanical properties of the X-CMCS/CS scaffolds
should be improved. Although the scaffolds have compressive moduli similar to those of
trabecular bone when dry, the moduli of the hydrated scaffolds are lower than desired.
Perhaps, some sort of fiber or particle reinforcement could be used to improve the
mechanical properties of the scaffolds. For example, the inclusion of small polyester
fibers into the beads could potentially increase their compressive strength and modulus.
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